Mantle cell lymphoma: Observation to transplantation

Babak Rajabi, John W. Sweetenham

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

Mantle cell lymphoma as a rare non-Hodgkin B-cell lymphoma can present in different clinical presentations such as an aggressive form or a more indolent picture. Treatment modality is based on multiple factors including age, presence or absence of symptoms, and comorbidities. Watchful waiting is a reasonable approach for asymptomatic patients especially in elderly. In symptomatic patients, treatment is chemo-immunotherapy followed by maintenance immunotherapy or autologous bone marrow transplant. Allogeneic bone marrow transplant has a potential benefit of cure for relapsed/refractory cases, but it has a high mortality rate. Novel treatment with agents such as ibrutinib, a Bruton tyrosine kinase inhibitor, has shown promising results in relapse/refractory cases. We extensively review the most recent data on diagnostic and therapeutic management of mantle cell lymphoma through presenting two extreme clinical scenarios.

Original languageEnglish (US)
Pages (from-to)37-48
Number of pages12
JournalTherapeutic Advances in Hematology
Volume6
Issue number1
DOIs
StatePublished - Feb 2015
Externally publishedYes

Keywords

  • chemo-immunotherapy
  • ibrutinib
  • mantle cell lymphoma
  • transplantation

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Mantle cell lymphoma: Observation to transplantation'. Together they form a unique fingerprint.

  • Cite this